hepatocellular carcinoma
Conditions
Interventions
1:PD-1 inhibitor and TACE
Sponsors
Shanghai Public Health Clinical Center
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.Aged 18-75 years; 2.CNCL(2019) stage I-IIIa,HCC is diagnosed by pathologist after hepatectomy; 3.HIV infection; Accepted HAART at least 1 week before operation and continue more than 2 years after operation. 4.Gd-EOB-DTPA enhanced MRI, DSA, chest CT do not find intra-/extra-liver tumor is found 4+/-1 weeks after operation.
Exclusion criteria
Exclusion criteria: 1.Patients with other special infections should not be treated by operation or immunotherapy; 2.Not R0 resection or intra-/extra-liver tumor is found 4+/-1 weeks after operation; 3.PVTT type III-IV; 4.Over screening schedule date; 5.Ever used PD-1/PD-L1 inhibitor or other anti-tumor medicine 4 weeks before or after operation; 6.Child-Pugh score >=8 or with ascites, Cr>UN,eGFR<90,WBC<=3.0E+9/L,PLT<=60E+9/L,abnormal thyroid function,ECOG score 2-4; 7.Combind with immuno-disease, sentive to PD-1 inhibitor,mild/severe pheumonia, myocarditis,heart funtion equal or more than grade 2,pregnancy,active viral hepatitis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Recurrence free survival time within two years after operation; | — |
Contacts
Public ContactYangqing Huang
Shanghai Public Health Clinical Center
Outcome results
None listed